Compare CZFS & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CZFS | CRNX |
|---|---|---|
| Founded | 1984 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.7M | 3.9B |
| IPO Year | 1995 | 2018 |
| Metric | CZFS | CRNX |
|---|---|---|
| Price | $60.31 | $33.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $74.78 |
| AVG Volume (30 Days) | 5.9K | ★ 1.0M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.32% | N/A |
| EPS Growth | ★ 30.26 | N/A |
| EPS | ★ 7.62 | N/A |
| Revenue | ★ $9,881,000.00 | $1,039,000.00 |
| Revenue This Year | N/A | $722.66 |
| Revenue Next Year | $2.64 | $183.79 |
| P/E Ratio | $7.90 | ★ N/A |
| Revenue Growth | ★ 2.82 | N/A |
| 52 Week Low | $49.99 | $24.10 |
| 52 Week High | $69.30 | $57.99 |
| Indicator | CZFS | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 44.08 | 29.20 |
| Support Level | $58.03 | $33.23 |
| Resistance Level | $63.69 | $37.23 |
| Average True Range (ATR) | 2.13 | 1.62 |
| MACD | 0.03 | 0.13 |
| Stochastic Oscillator | 38.36 | 8.33 |
Citizens Financial Services Inc is a Pennsylvania-chartered bank and trust company. The company through its banking subsidiary provides banking activities and services for individual, business, governmental and institutional customers. Its activities and services principally include checking, savings, and time deposit accounts; residential, commercial and agricultural real estate, commercial and industrial, state and political subdivision and consumer loans; and a variety of other specialized financial services. The Trust and Investment division of the Bank offers a full range of client investment, estate, mineral management, and retirement services.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.